230 related articles for article (PubMed ID: 16512779)
1. Pharmacogenetics in clinical practice: considerations for testing.
Constable S; Johnson MR; Pirmohamed M
Expert Rev Mol Diagn; 2006 Mar; 6(2):193-205. PubMed ID: 16512779
[TBL] [Abstract][Full Text] [Related]
2. Interpreting P values in pharmacogenetic studies: a call for process and perspective.
Maitland ML; Ratain MJ; Cox NJ
J Clin Oncol; 2007 Oct; 25(29):4513-5. PubMed ID: 17925544
[No Abstract] [Full Text] [Related]
3. Pharmacogenetics: the Dx perspective.
Cartwright CP
Expert Rev Mol Diagn; 2001 Nov; 1(4):371-6. PubMed ID: 11901851
[TBL] [Abstract][Full Text] [Related]
4. Pharmacogenetic testing in psychiatry: a review of features and clinical realities.
de Leon J; Arranz MJ; Ruaño G
Clin Lab Med; 2008 Dec; 28(4):599-617. PubMed ID: 19059065
[TBL] [Abstract][Full Text] [Related]
5. Safety and nutritional assessment of GM plants and derived food and feed: the role of animal feeding trials.
EFSA GMO Panel Working Group on Animal Feeding Trials
Food Chem Toxicol; 2008 Mar; 46 Suppl 1():S2-70. PubMed ID: 18328408
[TBL] [Abstract][Full Text] [Related]
6. Translating genomic biomarkers into clinically useful diagnostics.
Ginsburg GS; Haga SB
Expert Rev Mol Diagn; 2006 Mar; 6(2):179-91. PubMed ID: 16512778
[TBL] [Abstract][Full Text] [Related]
7. Evaluating the value of genomic diagnostics: implications for clinical practice and public policy.
Issa AM
Adv Health Econ Health Serv Res; 2008; 19():191-206. PubMed ID: 19548519
[TBL] [Abstract][Full Text] [Related]
8. FDA perspectives on pharmacogenetic testing.
Harper CC; Philip R; Robinowitz M; Gutman SI
Expert Rev Mol Diagn; 2005 Sep; 5(5):643-8. PubMed ID: 16149867
[TBL] [Abstract][Full Text] [Related]
9. Pharmacogenetics: the Rx perspective.
Renegar G; Rieser P; Manasco P
Expert Rev Mol Diagn; 2001 Sep; 1(3):255-63. PubMed ID: 11901830
[TBL] [Abstract][Full Text] [Related]
10. Ancillary risk information and pharmacogenetic tests: social and policy implications.
Henrikson NB; Burke W; Veenstra DL
Pharmacogenomics J; 2008 Apr; 8(2):85-9. PubMed ID: 17486108
[TBL] [Abstract][Full Text] [Related]
11. Improving the power of diagnostics in the era of targeted therapy and personalized healthcare.
Walk EE
Curr Opin Drug Discov Devel; 2010 Mar; 13(2):226-34. PubMed ID: 20205056
[TBL] [Abstract][Full Text] [Related]
12. Pharmacogenetics: from bench to byte.
Swen JJ; Wilting I; de Goede AL; Grandia L; Mulder H; Touw DJ; de Boer A; Conemans JM; Egberts TC; Klungel OH; Koopmans R; van der Weide J; Wilffert B; Guchelaar HJ; Deneer VH
Clin Pharmacol Ther; 2008 May; 83(5):781-7. PubMed ID: 18253145
[TBL] [Abstract][Full Text] [Related]
13. Current impact of gene technology on healthcare. A map of economic assessments.
Rogowski W
Health Policy; 2007 Feb; 80(2):340-57. PubMed ID: 16678930
[TBL] [Abstract][Full Text] [Related]
14. Pharmacogenetics and cost-effectiveness analysis: a two-way street.
Chalkidou K; Rawlins M
Drug Discov Today; 2011 Oct; 16(19-20):873-7. PubMed ID: 21903176
[TBL] [Abstract][Full Text] [Related]
15. Risk assessment and pharmacogenetics in molecular and genomic epidemiology.
Park SK; Choi JY
J Prev Med Public Health; 2009 Nov; 42(6):371-6. PubMed ID: 20009483
[TBL] [Abstract][Full Text] [Related]
16. [Cost-effectiveness evaluation of predictive molecular diagnostics using the example of hereditary non-polyposis colorectal cancer (HNPCC)].
Hagen A; Hessabi HK; Gorenoi V; Schönermark MP
Gesundheitswesen; 2008 Jan; 70(1):18-27. PubMed ID: 18273760
[TBL] [Abstract][Full Text] [Related]
17. Applications of microarrays and biochips in pharmacogenomics.
Hardiman G
Methods Mol Biol; 2008; 448():21-30. PubMed ID: 18370228
[TBL] [Abstract][Full Text] [Related]
18. Harnessing economic drivers for successful clinical implementation of pharmacogenetic testing.
Deverka PA; McLeod HL
Clin Pharmacol Ther; 2008 Aug; 84(2):191-3. PubMed ID: 18679180
[TBL] [Abstract][Full Text] [Related]
19. Anticipating clinical integration of pharmacogenetic treatment strategies for addiction: are primary care physicians ready?
Shields AE; Lerman C
Clin Pharmacol Ther; 2008 Apr; 83(4):635-9. PubMed ID: 18323859
[TBL] [Abstract][Full Text] [Related]
20. Strategy for genotoxicity testing: hazard identification and risk assessment in relation to in vitro testing.
Thybaud V; Aardema M; Clements J; Dearfield K; Galloway S; Hayashi M; Jacobson-Kram D; Kirkland D; MacGregor JT; Marzin D; Ohyama W; Schuler M; Suzuki H; Zeiger E;
Mutat Res; 2007 Feb; 627(1):41-58. PubMed ID: 17126066
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
